Characterization of phentermine and related compounds as monoamine oxidase (MAO) inhibitors.
Level 5 - mechanism / opinion, no new human data
In vitro bench study using rat tissues
PubMed 10799660 · doi:10.1016/s0006-2952(00)00306-3
What was done
Researchers measured the inhibitory effects of phentermine and related unlabeled compounds (including pseudoephedrine, ephedrine, norephedrine, and estradiol benzoate) on monoamine oxidase (MAO-A and MAO-B) activities. Assays were conducted using rat lung, brain, and liver tissues with serotonin and beta-phenylethylamine as substrates, testing individual drugs and combinations.
What was found
Phentermine inhibited MAO-A serotonin-metabolizing activity across rat lung, brain, and liver tissues with Ki values of 85-88 microM, exhibiting potency comparable to the MAO inhibitor antidepressants iproniazid and moclobemide. When phentermine was combined with other unlabeled reversible MAO inhibitors, the degree of MAO inhibition was additive.
Why it matters
This study provides an in vitro mechanistic rationale for adverse cardiopulmonary effects associated with fenfluramine-phentermine combinations, demonstrating that phentermine acts as an unlabelled MAO-A inhibitor that can additively block serotonin metabolism.
Limits
The study is limited to in vitro assays on rat tissues, lacking in vivo confirmation or human clinical data. The abstract reports no sample sizes (n), number of tissue replicates, or measures of statistical uncertainty.
Cited by
- context Ma Huang acts through monoamine oxidase B (MAO-B) enzyme functionality.